Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Saudi Arabia to keep hospital visits low with major primary healthcare project:

This article was originally published in Clinica

Executive Summary

To meet the strong demand for primary healthcare in Saudi Arabia, the ministry of health (MoH) has launched a Riyal17bn (US$1.8bn) project to build 2,000 primary healthcare centres (PHCs), which are to be linked electronically and each equipped with an e-patient health records system. PHCs receive over 85% of the country's patients (58 million patient visits in 2005), with hospitals and other clinics receiving the balance of 15%, reports The Saudi Gazette. "Our emphasis is on a maximum utilisation of PHCs primarily to reduce people's need to visit hospitals," said Dr Nabeel Al-Qahtani, director general, PHC department for the MoH. The King Abdullah Primary Healthcare Project will develop the entirely state-owned centres in three phases over five years.

You may also be interested in...



EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel